Considerations in the development of live biotherapeutic products for clinical use |
| |
| Authors: | Ross Jennifer J Boucher Philip E Bhattacharyya Siba P Kopecko Dennis J Sutkowski Elizabeth M Rohan Patricia J Chandler Donna K F Vaillancourt Julienne |
| |
| Affiliation: | Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration/PHS, Rockville, MD, USA. jennifer.ross@fda.hhs.gov |
| |
| Abstract: | Food products in the United States (U.S.), including dietary supplements, may contain live microorganisms and can be promoted for general health, nutritional, or structure/function claims. In contrast, such preparations used with the intention of having a preventive or therapeutic effect in humans are regulated by the Food and Drug Administration (FDA) in the U.S. as biological products, specifically as live biotherapeutic products (LBPs). Discussion of considerations in the early development of LBPs may aid in preparation of an Investigational New Drug Application (IND) that is designed to collect clinical data to support marketing approval of a LBP in the U.S. for a specific clinical use. Product information is an important component of an IND to support a proposed clinical study. |
| |
| Keywords: | |
| 本文献已被 PubMed 等数据库收录！ |
|
